Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB

Viatris

Status and phase: Completed; Phase 4

Conditions: Urinary Incontinence

Treatments: Drug: tolterodine SR, overactive bladder

Study type: Interventional

Funder types: Industry

Identifiers

NCT00143377

A6121122

Details and patient eligibility

About

The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years or older patients suffering from OAB symptoms (urinary frequency of at least 8 micturitions per 24h, urinary urgency and at least 3 urge urinary incontinence episodes within 3 days), confirmed by a micturition bladder diary.

Exclusion criteria

• Other than urge incontinence
• History of prostate/uterine or other female organ cancer

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind